来源:[1] 默克在其摇钱树专利悬崖期到来之前获得一项关键批准 (https://finance.yahoo.com/m/cd506ba7-c40c-3fd ...)[2] 随着独占期即将结束,默克赢得Keytruda皮下注射剂批准 - BioSpace (https://www.biospace.com/article/as-exclusivi ...)[3] 默克的Keytruda Qlex:竞争差异化和肿瘤市场扩张的战略飞跃 - AInvest (https://vertexaisearch.cloud.google.com/groun ...)